We are live on ! Find out more
NGM

NGM Biopharmaceuticals, Inc. Common Stock
NGM

Delisted

NGM was delisted on the 4th of April, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in NGM Biopharmaceuticals, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 74 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 75 → 0 (-75)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $55.1M → $0 (-$55.1M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 74

Holders
–
Holders Change
-75
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
74
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CG
Column Group
California
-$28.8M
2
BlackRock
BlackRock
New York
-$4.78M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$3.7M
4
SG
StepStone Group
California
-$2.5M
5
EC
Euclidean Capital
New York
-$1.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
HWAM
26
Hennion & Walsh Asset Management
New Jersey
– -$112K -70,636 Closed
RhumbLine Advisers
27
RhumbLine Advisers
Massachusetts
– -$105K -66,344 Closed
Millennium Management
28
Millennium Management
New York
– -$105K -66,180 Closed
AllianceBernstein
29
AllianceBernstein
Tennessee
– -$102K -64,310 Closed
VF
30
Virtu Financial
New York
– -$77K -48,708 Closed
Jane Street
31
Jane Street
New York
– -$76.7K -48,238 Closed
SO
32
STRS Ohio
Ohio
– -$73K -46,000 Closed
UBS Group
33
UBS Group
Switzerland
– -$72.2K -45,436 Closed
Fidelity Investments
34
Fidelity Investments
Massachusetts
– -$55.7K -35,061 Closed
GCP
35
GSA Capital Partners
United Kingdom
– -$53K -33,529 Closed
Barclays
36
Barclays
United Kingdom
– -$48.1K -30,260 Closed
DM
37
Diker Management
New York
– -$47.7K -29,996 Closed
Two Sigma Investments
38
Two Sigma Investments
New York
– -$44.2K -27,800 Closed
CGL
39
Clarius Group LLC
Washington
– -$42.8K -26,912 Closed
XT
40
XTX Topco
Cayman Islands
– -$41.4K -26,022 Closed
Bank of America
41
Bank of America
North Carolina
– -$40.9K -25,721 Closed
Tudor Investment Corp
42
Tudor Investment Corp
Connecticut
– -$40K -25,147 Closed
CA
43
Carson Advisory
Georgia
– -$35.9K -22,550 Closed
EGM
44
Engineers Gate Manager
New York
– -$35.4K -22,269 Closed
AIG
45
American International Group
New York
– -$34.2K -21,480 Closed
Mirae Asset Global Investments
46
Mirae Asset Global Investments
South Korea
– -$80.9K -21,169 Closed
Principal Financial Group
47
Principal Financial Group
Iowa
– -$31.5K -19,796 Closed
OAM
48
Oxford Asset Management
United Kingdom
– -$30.9K -19,458 Closed
JRP
49
Jasper Ridge Partners
California
– -$30.6K -19,250 Closed
JP Morgan Chase
50
JP Morgan Chase
New York
– -$29.4K -18,500 Closed
1
2
3

NGM Hedge Fund Activity: Q2 2024 in Review

0 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q2 2024, worth a combined $0 — down 100% from $55.1M a quarter earlier.

Sellers outnumbered buyers: 74 funds closed out of NGM and 0 opened new positions — a net loss of 74 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Column Group, exiting entirely with an estimated $28.8M sold.

  • 0 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q2 2024, down from 75 in Q1 2024.
  • Funds reported $0 of NGM Biopharmaceuticals, Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
  • 0 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q2 2024 and 74 closed out, a net change of -74 holders.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q2 2024 was Column Group, an estimated $28.8M sold.

Based on aggregated 13F filings for Q2 2024.